Omalizumab super-responders
Based on our definition, 33.7%, (35/104) of OMA subjects who completed
trials were super-responders. That constituted 38.0%, (35/92) of OMA
responders.
OMA Super-responders (supplementary Table
E3) had significantly more exacerbations at baseline [Median(IQR),
super-responder: 6(2) vs non-super-responder: 4(4), P=0.029], were
less mOCS dependent [super-responder: 14.3%,(5/35) vs
non-super-responder: 65.2%,(45/69), P<0.001] and had a
lower prevalence of anxiety [super-responder: 16.7%(5/30) vs
non-super-responder: 38.3%,(23/60), P=0.036] and depression
[super-responder: 17.2%,(5/29) vs non-super-responder:
39.3%,(24/61), P=0.036]. Absence of depression and not being on mOCS
were independently associated with OMA super-response (Table 2).